Dynamics of the level of interleukin 31 and 33, cortisol and filaggrin in the blood serum of pregnant women with atopic dermatitis during treatment with a combination of an emollient and a topical antipruritic agent
https://doi.org/10.21518/ms2024-350
Abstract
Introduction. The widespread prevalence of atopic dermatitis and decreased quality of life make the problem urgent and require the search for new treatment methods. In atopic dermatitis, excessive expression of interleukins 31 and 33 in keratinocytes is noted. In patients with atopic dermatitis, there is an increase in serum cortisol and filaggrin levels. In recent years, active development of drugs has been carried out, aimed mainly at the immune component of the pathogenesis of atopic dermatitis. However, clinical trials of these drugs are not conducted on pregnant women. For the treatment of atopic dermatitis during pregnancy, we have proposed a regimen of external therapy, including a topical moisturizer and a topical antipruritic agent.
Aim. To evaluate the levels of interleukins 31, 33, cortisol and filaggrin in blood serum before and after treatment of atopic dermatitis with a combination of emollient and topical antipruritic agent.
Materials and methods. The examination included 76 pregnant women during an exacerbation of atopic dermatitis. The levels of interleukins 31, 33, cortisol and filaggrin were determined in the blood serum at the first visit and after 4 weeks of using the proposed combination of emollient and topical antipruritic agent using enzyme-linked immunosorbent assay (ELISA).
Results. Against the background of the proposed therapy, a statistically significant decrease in the concentration of interleukins 31 was noted from 28.98 to 2.08 pg/ml, filaggrin from 9.72 to 5.26 ng/ml, cortisol from 629.80 to 472.25 pg/ml (p = 0,001). There were no statistically significant fluctuations in interleukins 33 levels (p = 0,124).
Conclusion. The combination of external therapy with the use of an emollient and a topical antipruritic agent reduces the production of interleukins 31, cortisol and filaggrin in the blood serum, but the content of interleukins 33 does not change significantly.
About the Authors
E. A. Orlova
Penza Institute for Further Training of Physicians – branch of Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Ekaterina A. Orlova, Dr. Sci. (Med.), Associate Professor, Head of the Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology
8A, Stasov St., Penza, 440060
Yu. A. Kandrashkina
Penza Institute for Further Training of Physicians – branch of Russian Medical Academy of Continuing Professional Education;
Penza State University
Russian Federation
Russian Federation
Yulia A. Kandrashkina, Postgraduate Student, Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology, Penza Institute for Further Training of Physicians – branch of Russian Medical Academy of Continuing Professional Education; Senior Lecturer, Penza State University
8A, Stasov St., Penza, 440060,
40, Krasnaya St., Penza, 440026
O. A. Levashova
Penza Institute for Further Training of Physicians – branch of Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Olga A. Levashova, Cand. Sci. (Biol.), Associate Professor of the Department of Medical Microbiology and Laboratory Medicine
8A, Stasov St., Penza, 440060
E. M. Kostina
Penza Institute for Further Training of Physicians – branch of Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Elena M. Kostina, Dr. Sci. (Med.), Associate Professor, Professor of the Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology
8A, Stasov St., Penza, 440060
A. F. Shtakh
Penza State University
Russian Federation
Russian Federation
Aleksandr F. Shtakh, Cand. Sci. (Med.), Associate Professor, Head of the Department of Obstetrics and Gynecology
40, Krasnaya St., Penza, 440026
References
1. Shchegelskaya TYu, Tseytlin OYa, Migacheva NB. Simple and low-cost ways to improve atopic dermatitis treatment outcomes. Lechaschi Vrach. 2023;(11):13–20. (In Russ.) https://doi.org/10.51793/OS.2023.26.11.002.
2. Kovalenko YuA, Kruglova LS, Shatokhina EA. Current views on the mechanisms of development and pharmacotherapy of pruritus. Russian Journal of Clinical Dermatology and Venereology. 2021;20(1):90–96. (In Russ.) https://doi.org/10.17116/klinderma20212001190.
3. Feld M, Garcia R, Buddenkotte J, Katayama S, Lewis K, Muirhead G et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500–508.e24. https://doi.org/10.1016/j.jaci.2016.02.020.
4. Varlamov EE, Pampura AN, Sukhorukov VS. The importance of cytokines for the atopic dermatitis pathogenesis. Russian Bulletin of Perinatology and Pediatrics. 2018;63(1):28–33. (In Russ.) https://doi.org/10.21508/1027-4065-2018-63-1-28-33.
5. Saleem MD, Oussedik E, D’Amber V, Feldman SR. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591–599. https://doi.org/10.1080/09546634.2017.1290205.
6. Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL-33/ IL-31 Axis: A Potential Inflammatory Pathway. Mediators Inflamm. 2018:3858032. https://doi.org/10.1155/2018/3858032.
7. Poroshina AS, Shershakova NN, Shilovskiy IP, Kadushkin AG, Taganovich AD, Gudima GO, Khaitov MR. Role of IL-25, IL-33 and TSLP in the development of corticosteroid resistance. Immunologiya. 2023;44(4):500–510. (In Russ.) https://doi.org/10.33029/0206-4952-2023-44-4-500-510.
8. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Lüscher-Firzlaff J et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129(2):426–433.e8. https://doi.org/10.1016/j.jaci.2011.10.042.
9. Imai Y. Interleukin-33 in atopic dermatitis. J Dermatol Sci. 2019;96(1):2–7. https://doi.org/10.1016/j.jdermsci.2019.08.006.
10. Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. Br J Dermatol. 2014;170(1 Suppl.):38–43. https://doi.org/10.1111/bjd.13084.
11. Gutsol LO, Guzovskaiia EV, Serebrennikova SN, Seminskу IZh. Stress (general adaptation syndrome) lecture. Baikal Medical Journal. 2022;1(1):70–80. (In Russ.) https://doi.org/10.57256/2949-0715-2022-1-70-80.
12. Voronkova NA, Dontsova EV, Novikova LA, Borzunova LN. Atopic dermatitis: advancement and problems in understanding the essence of the disease and its treatment. Clinical Medicine (Russian Journal). 2020;98(9-10):650–655. (In Russ.) https://doi.org/10.30629/0023-2149-2020-98-9-10-650-655.
13. Meštrović-Štefekov J, Lugović-Mihić L, Hanžek M, Bešlić I, Japundžić I, Karlović D. Salivary Cortisol Values and Personality Features of Atopic Dermatitis Patients: A Prospective Study. Dermatitis. 2022;33(5):341–348. https://doi.org/10.1097/DER.0000000000000834.
14. Kandrashkina YuA, Orlova EA, Kostina EM. Studying the role of cortisol in the pathogenesis of atopic dermatitis during pregnancy. Meditsinskiy Sovet. 2024;18(2):28–32. (In Russ.) https://doi.org/10.21518/ms2024-011.
15. Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36–43. https://doi.org/10.1016/j.anai.2019.10.008.
16. Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol. 2006;126(6):1200–1202. https://doi.org/10.1038/sj.jid.5700365.
17. Kobiela A, Hovhannisyan L, Jurkowska P, de la Serna JB, Bogucka A, Deptuła M et al. Excess filaggrin in keratinocytes is removed by extracellular vesicles to prevent premature death and this mechanism can be hijacked by Staphylococcus aureus in a TLR2-dependent fashion. J Extracell Vesicles. 2023;12(6):e12335. https://doi.org/10.1002/jev2.12335.
18. Rasheed Z, Zedan K, Saif GB, Salama RH, Salem T, Ahmed AA et al. Markers of atopic dermatitis, allergic rhinitis and bronchial asthma in pediatric patients: correlation with filaggrin, eosinophil major basic protein and immunoglobulin E. Clin Mol Allergy. 2018;16:23. https://doi.org/10.1186/s12948-018-0102-y.
19. Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835–852. https://doi.org/10.1080/1744666X.2021.1940962.
20. Tamrazova OB, Dubovets NF, Tamrazova AV, Seleznev SP. Role of emollients in the prevention of skin diseases in young children. Meditsinskiy Sovet. 2021;(1):158–166. (In Russ.) https://doi.org/10.21518/2079-701X-2021-1-158-166.
21. Tamrazova OB, Stadnikova AS, Rudikova EV. Cutaneous manifestations in children with the new coronavirus infection COVID-19. RUDN Journal of Medicine. 2021;25(1):16–24. (In Russ.) https://doi.org/10.22363/2313-0245-2021-25-1-16-24.
22. Stadnikova AS, Tamrazova OB. Use of neotannin in the treatment of atopic dermatitis in infants. Dermatology in Russia. 2017;(S1):88. (In Russ.) Available at: https://www.elibrary.ru/zwzawz.
23. Kholodilova NA, Monakhov KN. New in itching correction in patients with itchy dermatosis. Russian Journal of Clinical Dermatology and Venereology. 2019;18(4):469–478. (In Russ.) https://doi.org/10.17116/klinderma201918041469.
24. Zaslavsky DV, Tulenkova ЕS, Monakhov KN, Kholodilova NA, Kondratieva YuS, Tamrazova OB et al. Eczema: tactics of choice external therapy. Vestnik Dermatologii i Venerologii. 2018;94(3):56–66. https://doi.org/10.25208/0042-4609-2018-94-3-56-66.
25. Kruglova LS, Shatokhina EA. The key role of an emollient with an active antipruritic component in the strategy for improving the quality of life of elderly patients with itching due to xerosis. Farmateka. 2022;29(14):62–68. (In Russ.) https://doi.org/10.18565/pharmateca.2022.14.62-68.
26. Кубанов АА, Намазова-Баранова ЛС, Хаитов РМ, Ильина НИ, Алексеева ЕА, Амбарчян ЭТ и др. Атопический дерматит: клинические рекомендации. М.; 2021. 81 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/265_2.
27. Murdaca G, Greco M, Tonacci A, Negrini S, Borro M, Puppo F, Gangemi S. IL-33/ IL-31 Axis in Immune-Mediated and Allergic Diseases. Int J Mol Sci. 2019;20(23):5856. https://doi.org/10.3390/ijms20235856.
Review
For citations:
Orlova EA, Kandrashkina YA, Levashova OA, Kostina EM, Shtakh AF. Dynamics of the level of interleukin 31 and 33, cortisol and filaggrin in the blood serum of pregnant women with atopic dermatitis during treatment with a combination of an emollient and a topical antipruritic agent. Meditsinskiy sovet = Medical Council. 2024;(14):118-123. (In Russ.) https://doi.org/10.21518/ms2024-350
Views:
442
Email this article 